Clinical Trials
22 trialsNCT01790152 2026-05-18
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Children's Oncology Group
Recruiting
NCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07584499 2026-05-13
MRG003
Sun Yat-sen University
Phase 1 Recruiting
NCT04619056 2026-05-12
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
CEBIOTEX
Phase 1 Completed
NCT04337177 2026-05-11
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Active not recruiting
NCT07297979 2026-05-08
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Amgen
Phase 1 Recruiting
NCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT06132503 2026-05-04
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Lantern Pharma Inc.
Phase 1 Recruiting
NCT06721689 2026-04-15
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT02945800 2026-04-02
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05046314 2026-03-19
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2 Completed
NCT07156565 2026-03-17
ATLAS
Ratio Therapeutics, Inc.
Phase 1 Recruiting
NCT07444918 2026-03-03
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05084430 2026-01-22
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT04540588 2025-12-02
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
Phase NA Completed
NCT06156410 2025-11-14
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT00544115 2025-06-10
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting